Download Speaker Bios - Drugging Transcription

SCOTTA.ARMSTRONG,M.D.,Ph.D.
Chair,DepartmentofPediatricOncology,Dana-FarberCancerInstitute
Dr.Armstrongisapediatriconcologistandleaderinleukemiaresearchwhose
studieshaveledtoseveralfindingsthatpointtopromisingnewtherapies.Among
Dr.Armstrong’smostnotableachievementswastheidentificationofrareleukemia
stemcellsinMLL-rearrangedleukemias,alethalformofleukemiathatisfoundin
childrenandadults.Inrelatedwork,Dr.Armstrong’sgrouphasbeenstudyingthe
roleofhistonemodificationsandchromosomestructureasacriticalinitialstepin
leukemiadevelopment,whichhaspromptedasearchfortherapiesthatcanreverse
thisprocessanderadicateleukemiacells.Thisworkledtothedevelopmentofnew
therapiesthatarenowbeingtestedinpatients.
Dr.ArmstrongreceivedhisMDandPhDfromtheUniversityofTexasSouthwestern
MedicalSchoolinDallas,Texas.Heperformedhisresidencyandfellowshipin
pediatrichematology/oncologyatChildren’sHospitalBoston,theDanaFarber
CancerInstitute,andHarvardMedicalSchool.Dr.Armstronghasbeenawardedthe
TillandMcCullochAwardfromtheInternationalSocietyofExperimental
Hematology,thePaulMarksPrizeforCancerResearchfromMemorialSloan
KetteringCancerCenter,theE.MeadJohnsonAwardforOutstandingResearchin
PediatricsandtheDameshekPrizefromtheAmericanSocietyofHematology.
BRADLEYE.BERNSTEIN,M.D.,Ph.D.
ProfessorofPathology,MassachusettsGeneralHospital
BradleyBernsteinistheBernardandMildredKaydenResearchInstituteChairanda
ProfessorofPathologyatMassachusettsGeneralHospital,aBroadInstitute
Member,andanAmericanCancerSocietyResearchProfessor.Bernstein’sresearch
focusesonepigenetics—changesingeneactivitygovernedbyinfluencesoutside
thegenesthemselves—andspecificallyhowmodificationstotheproteinscaffold
calledchromatincontributetomammaliandevelopmentandhumancancer.
BernsteinreceivedhisB.S.fromYaleUniversityandhisM.D.andPh.D.fromthe
UniversityofWashington,beforecompletingaresidencyinclinicalpathologyand
postdoctoralresearchatHarvardUniversity.HonorsincludethePaulMarksPrize
forCancerResearch,anEarlyCareerScientistawardfromtheHowardHughes
MedicalInstitute,andaCareerAwardintheBiomedicalSciencesfromthe
BurroughsWellcomeFund.
JAMESE.BRADNER,M.D.
President,NovartisInstitutesforBioMedicalResearch
PriortojoiningNovartisDr.BradnerservedontheresearchfacultyofHarvard
MedicalSchoolandasanattendingphysicianinstemcelltransplantationwithinthe
DepartmentofMedicalOncologyattheDana-FarberCancerInstitute.Theresearch
focusoftheBradnerlaboratoryhasbeenthestudyofBETbromodomainproteins
andtheirfunctioningenecontrol,innovatingchemicalprobesandinvestigational
drugstostudyandtreatcancer.Dr.Bradnerisaco-founderoffivebiotechnology
companiesandhasco-authoredmorethan150scientificpublicationsand30United
Statespatentapplications.
Dr.BradnerisagraduateofHarvardCollegeandtheUniversityofChicagoPritzker
SchoolofMedicine.HecompletedresidencyinMedicineatBrigham&Women's
Hospital,fellowshipsinMedicalOncologyandHematologyattheDana-Farber
CancerInstituteandpostdoctoraltraininginChemistryandChemicalBiologyat
HarvardUniversity(Prof.StuartSchreiber).Heistherecipientofmanyhonorific
awardsandwaselectedintotheAmericanSocietyofClinicalInvestigationin2011
andtheAlphaOmegaAlphaHonorMedicalSocietyin2013.
ROBERTA.COPELAND,Ph.D.
President,ResearchandChiefScientificOfficer,Epizyme,Inc.
RobertA.Copeland,Ph.D.isPresidentofResearchandChiefScientificOfficerat
Epizyme,Inc.HejoinedEpizymeinSeptember2008,fromGlaxoSmithKline,where
hewasVicePresidentofCancerBiology,OncologyCenterofExcellenceinDrug
Discovery.Dr.Copelandhasalsoservedonanumberofadvisoryboards,
committeesandeditorialboardsinindustry,academia,professionalsocietiesand
professionaljournals.BeforejoiningGSKheheldscientificstaffpositionsatMerck
ResearchLaboratories,DuPont-MerckandBristol-MyersSquibbandafaculty
positionattheUniversityofChicago,PritzkerSchoolofMedicine.Dr.Copeland
receivedhisB.S.inchemistryfromSetonHallUniversity,hisdoctorateinchemistry
fromPrincetonUniversityanddidpostdoctoralstudiesastheChaimWeizmann
FellowattheCaliforniaInstituteofTechnology.
Hisresearchinterestisinelucidatingthedeterminantsofdrugrecognitionbytheir
biologicaltargets,andtheuseofthisinformationinthediscoveryanddesignofnew
medicines.Acommonthemethroughouthisresearchhasbeentheroleofprotein
dynamicsindrug-targetinteractions.In2006Dr.Copelandformulatedthedrugtargetresidencetimemodel,anovel,alternativeapproachtodrugoptimizationthat
hasbeenwidelyadoptedthroughoutthebiotechnologyandpharmaceutical
industries.Hehascontributedtodrugdiscoveryanddevelopmenteffortsacross
multipletherapeuticareas,leadingto18drugcandidatesenteringhumanclinical
trials.Theseincludethecancerdrugsforetinib,afuresertib,pinometostat,
tazemetostat,Tafinlar(dabrafenib)andMekinist(trametinib)andtheantibiotic
Altabax(retapamulin).Dr.Copelandhascontributedmorethan200publicationsto
thescientificliterature,holds13issuedU.S.patentsandhasauthored5booksinthe
areasofproteinscienceandenzymology.
Hismostrecentbook,EvaluationofEnzymeInhibitorsinDrugDiscovery:AGuide
forMedicinalChemistsandPharmacologists,2ndEdition(Wiley,Hoboken,NJ),
publishedinMarch2013.
LISADREW,Ph.D.
Director,OncologyBioscience,AstraZenecaR&DBoston
LisaDrewisDirectorofOncologyBioscienceatAstraZenecaR&DBostonlocatedin
Waltham,MA.Duringher16yearsworkingatAstraZeneca,DrDrewhasledthe
progressionanddeliveryofmultipleoncologydrugdiscoveryprogramsfocusedon
targetingkinasesdrivingkeysignalingpathways,includingBRAF,CSF1RandALKas
thescientificleaderfromhitidentificationtocandidatedrugnomination.Currently,
sheisinvolvedinleadingthecelldeathstrategyforOncologyatAstraZenecaand
overseesthebiologyformultipleprogramsasateamleader.Lisaactively
participatesintheAstraZenecapostdoctoralprogramastheOncology
representativeaswellasthegraduateinternprogram.ShereceivedherBScin
BiologyandPhDincancercellbiologyfromUniversityofYork,Englandanddid
postdoctoraltrainingatUniversityofCalifornia,IrvineandColumbiaUniversity,
NewYorkbeforejoiningAstraZeneca.
RONALDM.EVANS,Ph.D.
ProfessorandDirectorGeneExpressionLaboratory,SalkInstituteforBiological
Studies
ProfessorEvansisDirectoroftheGeneExpressionLaboratoryandMetabolic
EngineeringProgramandCo-DirectoroftheHelmsleyCenterforGenomic
Medicine.Heisknownforpioneeringstudiesonhormonesignalinginphysiology
andindisease.HisdiscoveryoftheNuclearReceptorSuperfamilyprovidedaunified
signalingmechanismforsteroids,vitaminA,vitaminD,thyroidhormonesandbile
acids.Thesereceptorsusetranscriptiontocontrolsugar,salt,calcium,cholesterol
andfatmetabolism.Theyareprimarytargetsinbreast,prostateandpancreatic
cancers,andleukemiatreatment,andhavetherapeuticrolesinchronic
inflammation,osteoporosisandasthma.Hisworkonmusclemetabolismledtothe
discoveryof‘exercisemimetics,’whichpromotethebenefitsoffitnesswithout
training.Exercisemimeticswillhelpbattletheobesityepidemic,diabetes,heart
disease,hypertensionandcancer.HisworkonVitaminDuncoveredahidden
mechanismtoreprogrampancreaticcancerandincreaseitsresponseto
chemotherapy.HeisaHowardHughesMedicalInstituteInvestigatorandthe
recipientofmultipleawards,includingtheAlbertLaskerAward(2004)andthe
WolfPrize(2012),andisaMemberoftheNationalAcademyofSciencesandthe
InstituteofMedicine.
STEPHENFRYE,Ph.D.
Director,CenterforIntegrativeChemicalBiologyandDrugDiscovery,Universityof
NorthCarolinainChapelHill
AsdirectoroftheCenterforIntegrativeChemicalBiologyandDrugDiscoveryat
UNC,Dr.Fryeplaysakeyroleintranslationalresearchthroughcollaborativedrug
discoveryprojectswithotherUNCfaculty.Inaddition,hisCenterhasinitiateda
programintheareaofchemicalbiologyofchromatinregulation.Dr.Fryehasa
broadbackgroundindrugdiscoveryanddevelopmenthavingco-discovereda
marketedproducthimself(Avodart)andcreatedadepartmentthatdiscoveredtwo
FDAapprovedkinaseinhibitoroncologytherapies(LapatinibandPazopanib)while
atGSK.SincejoiningUNCin2007,Dr.Frye’sCenterhasbeendesignatedasoneof
theNationalCancerInstitute’schemicalbiologycenters.Dr.FryereceivedhisPh.D.
inorganicchemistryfromUNCChapelHillunderthementorshipofthelateProf.
ErnestEliel.Heistheauthorofover100patentsandpublications.
NATHANAELS.GRAY,Ph.D.
Professor,BiologicalChemistryandMolecularPharmacology,HarvardMedical
School
NathanaelGrayspenthischildhoodinZambia,Yemen,IndiaandSudanbefore
returningtotheUStoattendhighschoolatBerkeleyHighinCalifornia.Nathanael
GrayreceivedhisPhDinorganicchemistryfromtheUniversityofCaliforniaat
Berkeleyin1999wherehediscoveredPurvalanol,oneofthefirstselective
inhibitorsofcyclin-dependentkinases.HethenmovedtotheGenomicsInstituteof
theNovartisResearchFoundationinSanDiego,whereafterservingasastaff
scientistandgroupleaderofkinaseinhibitorchemistry,hewasnameddirectorof
biologicalchemistryin2001.Dr.Gray’sresearchteamwasresponsibleforthe
developmentofseveralclinicalcandidates,includingBAF312whichiscurrently
undergoingphaseIIIclinicaltrialsforthetreatmentofMultipleSclerosis.Dr.Gray
joinedthefacultyofHarvardMedicalSchoolandtheDanaFarberCancerInstitutein
2006tocontinuehisresearchusingsyntheticchemistryandfunctionalsmall
moleculediscoverytomodulatebiologicalpathwaysimportantincancer.His
researchgrouphasbeenresponsibleforthediscoveryofnovelinhibitorsofwildtypeandmutantformsofEGFR(WZ4002),mTor(Torin1andTorin2),Bcr-Abl
(GNF-2,GNF-5,HG-7-85-01),Mps1(Mps1-IN-1Mps1-IN-2),Erk5(XMD8-92),b-Raf,
LRRK2(LRRK2-IN-1),Jnk1,2,3(JNK-IN-7)andEphrinkinaseswhichhavebecome
widelyusedresearchtoolsandhaveinspiredseveraldrugdiscoveryprograms.
CIGALLKADOCH,Ph.D.
AssistantProfessor,PediatricOncology,HarvardMedicalSchool
CigallKadochisanAssistantProfessorofPediatricOncologyattheDana-Farber
CancerInstituteandHarvardMedicalSchoolandanInstituteMemberoftheBroad
InstituteofMITandHarvard.Dr.Kadochstudieschromatinregulation,withstrong
focusonthestructureandfunctionofthemammalianSWI/SNForBAFfamilyof
chromatinremodelingcomplexesinhumancancer.Herworkhasbeencenteredin
mechanisticallyinterrogatingrare,molecularlywell-definedcancers,tounderstand
therolethesecomplexesplayinpromotingawiderangeofmorecommoncancer
types.
KadochcompletedhergraduateandpostdoctoralresearchattheStanford
UniversitySchoolofMedicine.Workingalongsiderenowneddevelopmental
biologistGeraldCrabtree,sheusedaseriesofbiochemicalexperimentstoidentifya
novelsetofproteins,componentsofthemSWI/SNForBAFcomplex,whichregulate
chromatinstructure.Uponthesediscoveries,Kadochandhercolleaguesthenlinked
mutationsinthesubunitsofBAFcomplexestomorethanone-fifthofhuman
cancers.Inaddition,sheworkedtouncovertheprecisemechanismofBAFcomplex
perturbationinarare,aggressivesoft-tissuesarcoma,knownassynovialsarcoma.
Kadochisnowdevelopingnewapproachestothestructuralandfunctional
interrogationofchromatinregulatorsanddevelopingtherapeuticapproachesfor
cancersdrivenbyBAFmutations.
KadochearnedherundergraduatedegreeinMolecularandCellBiologyfromthe
UniversityofCalifornia,Berkeley,andherPh.D.inCancerBiologyfromtheStanford
UniversitySchoolofMedicine.In2014,shortlybeforebecomingoneoftheyoungest
AssistantProfessorsappointedtothefacultyofHarvardMedicalSchool,shewas
namedtoForbesMagazine’s30Under30inScience&Healthcare,andin2015,the
MITTechnologyReviewTopInnovatorsUnder35.Sheisalsotherecipientofthe
NIHDirector’sNewInnovatorAwardandwasrecentlynamedaPew-Stewart
ScholarinCancerResearch.
ANGELAKOEHLER,Ph.D.
AssistantProfessor,DepartmentofBiologicalEngineering,MIT
AngelaKoehleristheKarlVanTasselAssistantProfessorintheDepartmentof
BiologicalEngineeringatMITandanintramuralmemberoftheDavidH.Koch
InstituteforIntegrativeCancerResearchatMIT.SheisalsoanAssociateMemberof
theBroadInstitute.Herresearchgroupaimstodiscoveranddevelopfunctional
small-moleculeprobesoftranscriptionalregulators,includingchromatinmodifying
enzymesandoncogenictranscriptionfactors.Validatedprobesmaybeusedto
advancetheunderstandingoftranscriptionindevelopmentanddisease.Selected
probesmaybedevelopedintoimagingagents,diagnostictools,ortherapeuticleads.
AngelareceivedherB.A.inBiochemistryandMolecularBiologyfromReedCollege
in1997.In2003,shereceivedherPh.D.inChemistryfromHarvardUniversity.Upon
graduation,shebecameanInstituteFellowintheChemicalBiologyProgramatthe
BroadInstituteandaGroupLeaderfortheNCIInitiativeforChemicalGenetics.She
servesasFacultyCo-DirectoroftheHigh-ThroughputSciencesFacilityinthe
SwansonBiotechnologyCenterattheKochInstituteandservesontheChemistsin
CancerResearchsteeringcommitteefortheAmericanAssociationforCancer
Research.HonorsincludebeingnamedaGenomeTechnologyYoungInvestigator
andaMerkinInstituteFellow.
ROSSL.LEVINE,M.D.
Director,MemorialSloanKetteringCenterforHematologicMalignancies
RossLevine,MD,isaMemberoftheHumanOncologyandPathogenesisProgram
andanAttendingPhysicianontheLeukemiaService,DepartmentofMedicineandis
theLaurenceJosephDineenChairinLeukemiaResearchandthedirectoroftheMSK
CenterforHematologicMalignancies.Dr.LevinereceivedhisABfromHarvard
CollegeandaM.D.fromJohnsHopkins.Dr.LevineservedasanResidentinInternal
MedicineattheMGHandsubsequentlyasaHematology-OncologyFellowatDFCI.
HethenjoinedGaryGilliland’slaboratoryasapostdoctoralfellowandperformed
kinomesequencingattheBroadInstitutetoidentifyJAK2V617FandMPLmutations
inMPNpatients.InSeptember2007hewasrecruitedtoMSKtotheHuman
OncologyandPathogenesisProgramwhileheseespatientsontheLeukemia
Service.Hislabinvestigatestheroleofsomaticmutationsinsignalingeffectorsand
inepigeneticmodifiersinMPNandinAML.
ERICR.OLSON,Ph.D.
ChiefScientificOfficer,SyrosPharmaceuticals
Erichas30yearsofexperienceinthebiopharmaindustry.PriortojoiningSyros
Pharmaceuticalsin2013,heheldseveralseniorpositionsatVertexPharmaceuticals
inresearch,developmentandcommercializationofcysticfibrosis(CF)drugsbased
onthe1989discoveryoftheCFgene.Duringthistimeheleddevelopmentteams
forKalydecoandOrkambiandservedastheCFfranchisehead.Inadditiontohis
workatVertex,Dr.Olsonheldpositionsininfectiousdiseasesandgeneexpression
atUpjohnandWarner-Lambert/Pfizer.Dr.OlsonearnedhisB.S.inMicrobiology
fromtheUniversityMinnesotaandaPh.D.inMicrobiologyandImmunologyfrom
theUniversityofMichigan.
MATTHEWSHAIR,Ph.D.
Professor,DepartmentofChemistryandChemicalBiology,HarvardUniversity
MatthewShairisaProfessorintheDepartmentofChemistryandChemicalBiology
atHarvardUniversity,anassociateoftheBroadInstituteandanaffiliateofthe
HarvardStemCellInstitute.Hislabstudiesthemechanisticbasisofhumandiseases,
identifiesnewtargets,anddevelopssmallmoleculetherapeutics.Hislaboratoryhas
discoveredthatinhibitionofCDK8andCDK19isanewtherapeuticapproachto
acutemyeloidleukemia(AML)involvingunanticipatedeffectsontranscriptionof
cellidentitygenes.Hehasalsousedsmallmoleculestodiscoverthatoxysterolbindingproteinsareadruggabledependencyofsolidtumorcells.Hislabisknown
fortheircreativesynthesisofcomplexnaturallyoccurringmolecules.Hehasbeen
therecipientofseveralawardsforhiswork,mostnotablytheRaymondandBeverly
SacklerPrizeinthePhysicalSciences-ChemistryadministeredbyTelAviv
UniversityandtheArthurC.CopeScholarAward.Hehasbeenafounderofseveral
biotechcompaniesincludingInfinityPharmaceuticals(Nasdaq:INFI),MakotoLife
SciencesandChemiderm.HehasalsobeenanadvisortoAriad,Enanta,BristolMyersSquibbandNovartis.Moleculescreatedinhislabforthetreatmentofcancer
havebeenlicensedbyMerckinoneofthelargestlicensingdealsofanacademic
preclinicalasset.
KIMBERLYSTEGMAIER,M.D.
AssociateProfessor,Pediatrics,HarvardMedicalSchool
KimberlyStegmaier,anAssociateProfessorofPediatricsatHarvardMedicalSchool
andaPrincipalInvestigatoratDana-FarberCancerInstitute(DFCI),hasadvanced
theapplicationofgenomicstodrugandproteintargetdiscoveryforpediatric
cancers.SheistheViceChairforPediatricOncologyResearchandCo-directorofthe
PediatricHematologicMalignancyProgramandanattendingphysicianproviding
clinicalcareinPediatricOncologyattheDana-FarberCancerInstituteandBoston
Children’sHospital.Dr.StegmaierisalsoanInstituteMemberoftheBroadInstitute
ofHarvardandMIT.
TheStegmaierlaboratorydevelopsandintegrateschemicalandfunctionalgenomic
approachestoidentifynewproteintargetsandsmall-moleculemodulatorsof
malignancywithaneyetowardclinicaltranslation.Thelaboratoryhasfocusedon
pediatricmalignanciesnotablefortheaberrancyofdifferentiationand/oroncogenic
activationoftranscriptionfactors:theacuteleukemias,neuroblastoma,andEwing
sarcoma.Multipleclinicaltrialshaveresultedfromherlaboratory’sresearch.Dr.
Stegmaierhaswonnumerousawardsforherwork,includingtheSPRYoung
InvestigatorAward,theSirWilliamOslerYoungInvestigatorAwardfromthe
InterurbanClinicalClub,aSU2CInnovativeResearchGrant,andthe2016E.Mead
JohnsonAwardforResearchinPediatrics.
Dr.StegmaierwaselectedtotheSocietyforPediatricResearchin2007andthe
AmericanSocietyforClinicalInvestigationin2009.Sheisastrongadvocatefor
pediatricresearch,servingasaCouncilMemberwiththeSocietyforPediatric
Researchfrom2013-2016andaSteeringCommitteeMemberwiththeAACR
PediatricCancerWorkingGroupfrom2011-2016.ShewasrecentlyawardedtheA.
CliffordBargerExcellenceinMentoringAwardfromHarvardMedicalSchoolforher
commitmenttotrainingthenextgenerationofpediatriccancerresearchers.
Dr.StegmaierreceivedherundergraduatedegreefromDukeUniversity,medical
degreefromHarvardMedicalSchool,andtrainedinPediatricsandPediatric
Hematology/OncologyatBostonChildren’sHospitalandtheDana-FarberCancer
Institute.
RICHARDA.YOUNG,Ph.D.
Professor,WhiteheadInstituteandMIT
RichardYoungisaProfessorattheWhiteheadInstituteandMIT.Dr.Youngstudies
generegulationinhealthanddisease.HehasservedasanadvisortotheWorld
HealthOrganization,theNationalInstitutesofHealthandnumerousscientific
societiesandjournals.Dr.Young’shonorsincludeMembershipintheNational
AcademyofSciencesandScientificAmericanhasrecognizedhimasoneofthetop
50leadersinscience,technologyandbusiness.Hehasfoundedandadvised
companiesinthebiotechnologyandpharmaceuticalindustry,andiscurrentlya
memberoftheBoardofDirectorsofSyrosPharmaceuticals.Dr.Youngisalsoan
aviatorandholdsacommercialpilotlicense.